← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
T cell injection targeting CD7 chimeric antigen receptor (T cell injection targeting CD7 chimeric antigen receptor)
PersonGen BioTherapeutics (Suzhou)…·FRα
6 trials
Overview
Program
T cell injection targeting CD7 chimeric antigen receptor
Overview
Company
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Overview
Modality
CGT
Overview
Target
FRα
Overview
Indication
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies.. Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated remarkable success in treating relapsed and refractory (R/R) B-cell hematological malignancies. Although the application of CAR-T therapy in acute myeloid leukemia (AML)…
Toxicology
CRS
Reported
Clinical
Safety signal
Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies.. Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated remarkable success in treating relapsed and refractory (R/R) B-cell hematological malignancies. Although the application of CAR-T therapy in acute myeloid leukemia (AML)…
Clinical
Program phase
PHASE_2